化学
小分子
体内
MAPK/ERK通路
药理学
活动站点
药物发现
结构-活动关系
体外
信号转导
计算生物学
组合化学
酶
生物化学
生物
生物技术
作者
Richard A. Ward,Paul A. Bethel,Calum Cook,Emma Jane Davies,J.E. Debreczeni,Gary Fairley,Lyman J. L. Feron,Vikki Flemington,Mark A. Graham,Ryan D. R. Greenwood,Nicola Griffin,Lyndsey L. Hanson,Philip J. Hopcroft,Tina D. Howard,Julian A. Hudson,Michael James,Clifford D. Jones,Christopher R. Jones,Scott G. Lamont,Richard J. Lewis
标识
DOI:10.1021/acs.jmedchem.7b00267
摘要
There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclinical models. This article reports on our recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-molecular-weight, modestly active, and highly promiscuous chemical start point, compound 4. To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was critical in the rapid exploration of this template to compound 35, which was active when tested in in vivo antitumor efficacy experiments.
科研通智能强力驱动
Strongly Powered by AbleSci AI